FDA WARNING_LETTER - Revive Rx LLC dba Revive Rx Pharmacy - February 07, 2025

The FDA issued a Warning Letter to Revive Rx LLC dba Revive Rx Pharmacy following an inspection conducted from January 27 to February 7, 2025. The inspection revealed serious deficiencies in the company"s drug product production practices, particularly concerning sterile preparations, which put patients at risk. The main violations included insanitary conditions that led to adulterated drug products under sections 501(a)(2)(A), 301(a), and 301(k) of the Federal Food, Drug, and Cosmetic Act (FDCA). Specific issues observed were exposing sterile drug products to sub-standard air quality, inadequate responses to microbial contamination in aseptic areas, media fills not performed under challenging conditions, insufficient smoke studies, failure to properly sterilize components, and inadequate routine environmental monitoring. While Revive Rx submitted corrective action plans, the FDA deemed several responses deficient. The agency cited a lack of interim measures to protect products, incomplete investigations into contamination events, and insufficient documentation or clarification regarding how fundamental issues, such as media fills and sterilization processes, would be immediately rectified. The FDA requires comprehensive and documented corrective actions to ensure patient safety and compliance.